As a PARP inhibitor (Poly ADP-Ribose Polymerase inhibitor), niraparib is an oral anticancer drug. It is mostly used to treat specific ovarian cancers, such as primary peritoneal, fallopian tube, and epithelial ovarian cancers. After a patient responds to platinum-based chemotherapy, the 100 mg formulation of Niraparib is frequently administered as a dose strength and is frequently used in maintenance therapy.

Mechanism of Action

Inhibiting the activity of PARP enzymes—more especially, PARP-1 and PARP-2—that are involved in DNA repair is how niraparib functions. These enzymes support genomic integrity and DNA damage repair in healthy cells. However, the DNA repair pathways are already weakened in cancer cells, particularly those that have mutations in the BRCA1 or BRCA2 genes. Niraparib stops the cancer cells from fixing their DNA by blocking PARP, which causes DNA damage to build up and eventually results in cell death. This specific method preserves healthy cells while slowing the growth of tumors.

Indications and Uses

Niraparib is indicated for:

Maintenance Treatment: For adult patients who are responding fully or partially to platinum-based chemotherapy and have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Regardless of whether a patient has a BRCA mutation or not, first-line maintenance therapy is recommended for patients with advanced ovarian cancer who have responded completely or partially to first-line platinum-based chemotherapy.

Advanced Ovarian Cancer: Patients with advanced illness who have received three or more previous chemotherapy regimens and have a deleterious or suspected harmful hereditary BRCA mutation are also eligible in some countries.

Dosage and Administration

Niraparib is taken orally once every day. Usually taken as three 100 mg capsules, the suggested starting dose is 300 mg daily. To lessen the risk of hematological toxicity, a lower initial dose of 200 mg per day (two 100 mg capsules) may be considered, depending on the patient’s weight and baseline platelet count.

With or without food, capsules should be taken at the same time every day. Until the condition worsens or there is intolerable toxicity, treatment should be continued.

Side Effects

Niraparib 100 Mg may have adverse effects, just like any other medicine. Among the frequent and severe side effects are:

Hematologic toxicity:

The low platelet count, or thrombocytopenia

Low red blood cell count, or anemia

Low neutrophil count, or neutropenia

Effects on the digestive system:

Feeling queasy

Throwing up

Constipation

Appetite loss

Weakness and exhaustion

Disorders of sleep and insomnia

Elevated blood pressure, or hypertension

Serious but uncommon side effects could include:

Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): These are uncommon but possibly fatal bone marrow diseases.

A rare neurological disorder known as posterior reversible encephalopathy syndrome (PRES) can cause headaches, seizures, and alterations in vision.

Complete blood counts and blood pressure checks should be performed on patients receiving Niraparib medication on a frequent basis, particularly in the initial months of treatment.

Precautions and Contraindications

Pregnancy and Lactation: When given to expectant mothers, niraparib may harm the fetus. It should not be used when pregnant or nursing.

Liver or renal Dysfunction: Niraparib should be used carefully and closely monitored in patients with moderate to severe liver or renal impairment.

Drug Interactions: Patients should let their doctor know about all medications they are taking, even if niraparib does not significantly interact with other drugs.

Monitoring: Throughout treatment, routine blood pressure, liver enzyme, and blood count monitoring is crucial.

Patient Counseling and Adherence

Even if they are feeling well, patients should be taught the value of sticking to their treatment plan. The therapy’s effectiveness may be diminished if doses are missed or treatment is stopped too soon. Since side effects are frequently treatable with supportive care or dose adjustments, they should be reported to medical professionals as soon as possible.

Storage and Handling

It is recommended that Niraparib 100 mg capsules be stored at room temperature (20°C to 25°C or 68°F to 77°F), dry, and away from direct sunlight. Keep out of children’s reach.

Conclusion

For women with ovarian cancer, niraparib 100 mg is a potential targeted oral medication, especially when used as maintenance therapy to extend remission after chemotherapy. It can specifically target cancer cells with impaired DNA repair pathways because of its PARP inhibitory action. Niraparib should be provided under an oncologist’s supervision with frequent follow-ups to guarantee safety and effectiveness, just like any other cancer treatment. For qualified patients, niraparib can dramatically increase progression-free survival and quality of life with appropriate care.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of 100 mg of niraparib?
The main conditions that niraparib is used to treat include primary peritoneal, fallopian tube, and ovarian cancers. Following initial chemotherapy treatment, it is frequently administered as maintenance therapy.

2. How is Niraparib administered?
Niraparib is an inhibitor of PARP. It functions by stopping cancer cells from fixing their DNA, which kills the cells—particularly those that have BRCA mutations.

3. How is 100 mg of Niraparib to be taken?
It is taken orally once a day, with or without food, and normally at the same time every day. Depending on adverse effects and personal tolerance, the dosage may be changed.

4. Is it safe to use Niraparib when pregnant?
An unborn child may be harmed by niraparib. Effective contraception should be used by women of reproductive age both during and after treatment.